Jiangsu Hengrui Pharmaceutical Co., Ltd. (600276)

Jiangsu Hengrui Pharmaceutical Co., Ltd. (600276)

Jiangsu Hengrui Pharmaceutical Co., Ltd. is a pharmaceutical and health enterprise engaged in pharmaceutical innovation, research and development, production and promotion of high-quality drugs. It was founded in 1970 and listed on Shanghai Stock Exchange in 2000. By the end of 2019, it has more than 24000 employees worldwide. It is a well-known supplier of anti-tumor drugs, surgical drugs and contrast agents in China, It is also the leading unit of the national anti-tumor drug technology innovation industry university research alliance, with the national targeted drug engineering technology research center and postdoctoral research workstation. In 2019, the company achieved an operating revenue of 23.29 billion yuan and a tax revenue of 2.43 billion yuan, and was ranked 47th in the top 50 list of global pharmaceutical enterprises.

In the practice of market competition, Hengrui medicine adheres to innovation as the driving force to build the core competitiveness. In recent years, the company has invested about 15% of the annual sales of R & D funds. In 2019, the company has invested 3.9 billion yuan in R & D funds, accounting for 16.7% of the sales revenue. The company has established R & D centers or branches in the United States, Europe, Japan and China, and has built a R & D team of more than 3400 people, including more than 2000 doctors, masters and more than 200 returnees. In recent years, the company has undertaken 44 national major special projects. Six innovative drugs, including erexib, apatinib, thiopefistine, pyrrolotinib, karelizumab and remazolam toluenesulfonate, have been approved for listing. A batch of innovative drugs are under clinical development, and a number of innovative drugs have been launched in the United States. The company has applied for 894 domestic invention patents in total, and has 201 domestic effective authorized invention patents, 286 foreign authorized patents in Europe, America and Japan, 2 second prizes of national science and Technology Progress Award and 1 gold prize of Chinese patent.

Based on the principle of "honesty, trustworthiness and quality first", Hengrui pharmaceutical ranks among the best in the domestic market in terms of market share of anti-tumor drugs, surgical anesthesia drugs, characteristic infusion and contrast agents. At present, the company has 19 preparations such as injections, oral preparations and inhalation anesthetics on the market in Europe, America and Japan, realizing the large-scale sales of domestic injections in Europe, America and Japan.

Ruiyi's life is full of perseverance. Hengrui pharmaceutical has been adhering to the concept of "scientific research oriented, creating a healthy life", with the overall goal of building a multinational pharmaceutical group of Chinese people, striving to forge ahead and be brave in innovation, and constantly realizing new leaps and breakthroughs in the development of the enterprise.

>> tungsten carbide rings gold